Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses

Author(s): Alicja E. Grzegorzewska *

Volume 26, Issue 25, 2019

Page: [4832 - 4851] Pages: 20

DOI: 10.2174/0929867325666180719121142

Price: $65

Abstract

Genetic polymorphisms within the interferon λ (IFN-λ) chromosomal region, mainly rs12979860 of IFN-λ4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- α and ribavirin. Strong linkage disequilibrium of IFNL4 rs12979860 with IFNL4 rs368234815, which is casually associated with HCV spontaneous and therapeutical eradication, at least partially explains favorable HCV outcomes attributed to major homozygosity in rs12979860. Effects of IFN-based antiviral treatment are associated with pretreatment expression of the IFN-λ1 receptor, expression of hepatic IFN-stimulated genes, production of IFN- λ4, and preactivation of the JAK-STAT signaling. Nowadays direct-acting antivirals (DAAs) became a potent tool in the treatment of hepatitis C, but IFN-λs are still under investigation as potential antivirals and might be an option in HCV infection (DAA resistance, recurrent viremia, adverse effects).

Patients with altered immunocompetence are especially prone to infections. In uremic subjects, polymorphisms within the IFN-λ chromosomal region associate with spontaneous HCV clearance, similarly like in the non-uremic population. Circulating IFN-λ3 shows a positive correlation with plasma titers of antibodies to surface antigen of hepatitis B virus (anti-HBs), which are crucial for protection against hepatitis B virus. More efficient anti-HBs production in the presence of higher IFN-λ3 levels might occur due to IFN-λ3-induced regulation of indoleamine 2,3-dioxygenase (IDO) expression. IFN-stimulated response element is a part of IDO gene promoter. It is worth further investigation whether IDO gene, circulating IDO, genetic polymorphisms within the IFN-λ region, and circulating IFN-λ3 act in concordance in immunological response to hepatotropic viruses.

Keywords: Antivirals, hepatitis B virus, hepatitis C virus, IFNL3, IFNL4, immunocompetence, interferon-λ3, vaccination.

« Previous Next »
[1]
Schweitzer, A.; Horn, J.; Mikolajczyk, R.T.; Krause, G.; Ott, J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015, 386(10003), 1546-1555.
[http://dx.doi.org/10.1016/S0140-6736(15)61412-X] [PMID: 26231459]
[2]
Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 2013, 57(4), 1333-1342.
[http://dx.doi.org/10.1002/hep.26141] [PMID: 23172780]
[3]
Rutkowski, B.; Lichodziejewska-Niemierko, M.; Grenda, R.; Czekalski, S.; Durlik, M.; Bautembach, S. Report on renal replacement therapy in Poland -2010; Drukonsul: Gdańsk, 2013.
[4]
Rosińska, M.; Parda, N.; Stępień, M. Hepatitis C in Poland in 2014. Przegl. Epidemiol., 2016, 70(3), 386-394.
[PMID: 27870539]
[5]
WHO More than 2 million people coinfected with HIV and hepatitis C., Available at:. http://www.who.int/hiv/mediacentre/news/hep-hiv-coinfected/en/ [Accessed July 6, 2017].
[6]
Grzegorzewska, A.E. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev. Vaccines, 2014, 13(11), 1317-1326.
[http://dx.doi.org/10.1586/14760584.2014.944508] [PMID: 25148051]
[7]
Grzegorzewska, A.E. Prophylactic vaccinations in chronic kidney disease: current status. Hum. Vaccin. Immunother., 2015, 11(11), 2599-2605.
[http://dx.doi.org/10.1080/21645515.2015.1034915] [PMID: 25911956]
[8]
Harnett, J.D.; Parfrey, P.S.; Kennedy, M.; Zeldis, J.B.; Steinman, T.I.; Guttmann, R.D. The long-term outcome of hepatitis B infection in hemodialysis patients. Am. J. Kidney Dis., 1988, 11(3), 210-213.
[http://dx.doi.org/10.1016/S0272-6386(88)80151-3] [PMID: 3344743]
[9]
Okuda, K.; Hayashi, H.; Yokozeki, K.; Kobayashi, S.; Kashima, T.; Irie, Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J. Gastroenterol. Hepatol., 1998, 13(1), 62-67.
[http://dx.doi.org/10.1111/j.1440-1746.1998.tb00547.x] [PMID: 9737574]
[10]
Schvarcz, R.; Yun, Z.B.; Sönnerborg, A.; Weiland, O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol., 1995, 46(1), 43-47.
[http://dx.doi.org/10.1002/jmv.1890460110] [PMID: 7623006]
[11]
Shepherd, J.; Brodin, H.; Cave, C.; Waugh, N.; Price, A.; Gabbay, J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess., 2004, 8(39), iii-iv, 1-125.
[http://dx.doi.org/10.3310/hta8390] [PMID: 15461877]
[12]
Kotenko, S.V.; Gallagher, G.; Baurin, V.V.; Lewis-Antes, A.; Shen, M.; Shah, N.K.; Langer, J.A.; Sheikh, F.; Dickensheets, H.; Donnelly, R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol., 2003, 4(1), 69-77.
[http://dx.doi.org/10.1038/ni875] [PMID: 12483210]
[13]
Sheppard, P.; Kindsvogel, W.; Xu, W.; Henderson, K.; Schlutsmeyer, S.; Whitmore, T.E.; Kuestner, R.; Garrigues, U.; Birks, C.; Roraback, J.; Ostrander, C.; Dong, D.; Shin, J.; Presnell, S.; Fox, B.; Haldeman, B.; Cooper, E.; Taft, D.; Gilbert, T.; Grant, F.J.; Tackett, M.; Krivan, W.; McKnight, G.; Clegg, C.; Foster, D.; Klucher, K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol., 2003, 4(1), 63-68.
[http://dx.doi.org/10.1038/ni873] [PMID: 12469119]
[14]
Donnelly, R.P.; Kotenko, S.V. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res., 2010, 30(8), 555-564.
[http://dx.doi.org/10.1089/jir.2010.0078] [PMID: 20712453]
[15]
Donnelly, R.P.; Dickensheets, H.; O’Brien, T.R. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol., 2011, 32(9), 443-450.
[http://dx.doi.org/10.1016/j.it.2011.07.002] [PMID: 21820962]
[16]
Ank, N.; West, H.; Bartholdy, C.; Eriksson, K.; Thomsen, A.R.; Paludan, S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol., 2006, 80(9), 4501-4509.
[http://dx.doi.org/10.1128/JVI.80.9.4501-4509.2006] [PMID: 16611910]
[17]
Kotenko, S.V. IFN-λs. Curr. Opin. Immunol., 2011, 23(5), 583-590.
[http://dx.doi.org/10.1016/j.coi.2011.07.007] [PMID: 21840693]
[18]
Marcello, T.; Grakoui, A.; Barba-Spaeth, G.; Machlin, E.S.; Kotenko, S.V.; MacDonald, M.R.; Rice, C.M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology, 2006, 131(6), 1887-1898.
[http://dx.doi.org/10.1053/j.gastro.2006.09.052] [PMID: 17087946]
[19]
Robek, M.D.; Boyd, B.S.; Chisari, F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol., 2005, 79(6), 3851-3854.
[http://dx.doi.org/10.1128/JVI.79.6.3851-3854.2005] [PMID: 15731279]
[20]
Doyle, S.E.; Schreckhise, H.; Khuu-Duong, K.; Henderson, K.; Rosler, R.; Storey, H.; Yao, L.; Liu, H.; Barahmand-pour, F.; Sivakumar, P.; Chan, C.; Birks, C.; Foster, D.; Clegg, C.H.; Wietzke-Braun, P.; Mihm, S.; Klucher, K.M. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology, 2006, 44(4), 896-906.
[http://dx.doi.org/10.1002/hep.21312] [PMID: 17006906]
[21]
Kelly, C.; Klenerman, P.; Barnes, E. Interferon lambdas: the next cytokine storm. Gut, 2011, 60(9), 1284-1293.
[http://dx.doi.org/10.1136/gut.2010.222976] [PMID: 21303914]
[22]
Yu, D.; Zhao, M.; Dong, L.; Zhao, L.; Zou, M.; Sun, H.; Zhang, M.; Liu, H.; Zou, Z. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes. Drug Des. Devel. Ther., 2016, 10, 163-182.
[PMID: 26792983]
[23]
Miller, D.M.; Klucher, K.M.; Freeman, J.A.; Hausman, D.F.; Fontana, D.; Williams, D.E. Interferon lambda as a potential new therapeutic for hepatitis C. Ann. N. Y. Acad. Sci., 2009, 1182, 80-87.
[http://dx.doi.org/10.1111/j.1749-6632.2009.05241.x] [PMID: 20074277]
[24]
Muir, A.J.; Shiffman, M.L.; Zaman, A.; Yoffe, B.; de la Torre, A.; Flamm, S.; Gordon, S.C.; Marotta, P.; Vierling, J.M.; Lopez-Talavera, J.C.; Byrnes-Blake, K.; Fontana, D.; Freeman, J.; Gray, T.; Hausman, D.; Hunder, N.N.; Lawitz, E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology, 2010, 52(3), 822-832.
[http://dx.doi.org/10.1002/hep.23743] [PMID: 20564352]
[25]
Zeuzem, S.; Asselah, T.; Angus, P.; Zarski, J.P.; Larrey, D.; Müllhaupt, B.; Gane, E.; Schuchmann, M.; Lohse, A.W.; Pol, S.; Bronowicki, J.P.; Roberts, S.; Arasteh, K.; Zoulim, F.; Heim, M.; Stern, J.O.; Nehmiz, G.; Kukolj, G.; Böcher, W.O.; Mensa, F.J. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir. Ther. (Lond.), 2013, 18(8), 1015-1019.
[http://dx.doi.org/10.3851/IMP2567] [PMID: 23558093]
[26]
Gane, E.J.; Stedman, C.A.; Hyland, R.H.; Ding, X.; Svarovskaia, E.; Symonds, W.T.; Hindes, R.G.; Berrey, M.M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med., 2013, 368(1), 34-44.
[http://dx.doi.org/10.1056/NEJMoa1208953] [PMID: 23281974]
[27]
Sulkowski, M.S.; Bourlière, M.; Bronowicki, J.P.; Asselah, T.; Pawlotsky, J.M.; Shafran, S.D.; Pol, S.; Mauss, S.; Larrey, D.; Datsenko, Y.; Stern, J.O.; Kukolj, G.; Scherer, J.; Nehmiz, G.; Steinmann, G.G.; Böcher, W.O. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology, 2013, 57(6), 2155-2163.
[http://dx.doi.org/10.1002/hep.26386] [PMID: 23504636]
[28]
European Association for Study of Liver.EASL Recommendations on treatment of hepatitis C 2015. J. Hepatol., 2015, 63(1), 199-236.
[http://dx.doi.org/10.1016/j.jhep.2015.03.025] [PMID: 25911336]
[29]
Myers, R.P.; Shah, H.; Burak, K.W.; Cooper, C.; Feld, J.J. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can. J. Gastroenterol. Hepatol., 2015, 29(1), 19-34.
[http://dx.doi.org/10.1155/2015/692408] [PMID: 25585348]
[30]
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J. Hepatol., 2017, 76(2), 370-398.
[http://dx.doi.org/10.1016/j.jhep.2017.03.021]
[31]
Pagliaccetti, N.E.; Chu, E.N.; Bolen, C.R.; Kleinstein, S.H.; Robek, M.D. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology, 2010, 401(2), 197-206.
[http://dx.doi.org/10.1016/j.virol.2010.02.022] [PMID: 20303135]
[32]
Murata, K.; Asano, M.; Matsumoto, A.; Sugiyama, M.; Nishida, N.; Tanaka, E.; Inoue, T.; Sakamoto, M.; Enomoto, M.; Shirasaki, T.; Honda, M.; Kaneko, S.; Gatanaga, H.; Oka, S.; Kawamura, Y.I.; Dohi, T.; Shuno, Y.; Yano, H.; Mizokami, M. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut, 2018, 67(2), 362-371.
[http://dx.doi.org/10.1136/gutjnl-2016-312653] [PMID: 27789659]
[33]
Prokunina-Olsson, L.; Muchmore, B.; Tang, W.; Pfeiffer, R.M.; Park, H.; Dickensheets, H.; Hergott, D.; Porter-Gill, P.; Mumy, A.; Kohaar, I.; Chen, S.; Brand, N.; Tarway, M.; Liu, L.; Sheikh, F.; Astemborski, J.; Bonkovsky, H.L.; Edlin, B.R.; Howell, C.D.; Morgan, T.R.; Thomas, D.L.; Rehermann, B.; Donnelly, R.P.; O’Brien, T.R. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet., 2013, 45(2), 164-171.
[http://dx.doi.org/10.1038/ng.2521] [PMID: 23291588]
[34]
Ferraris, P.; Chandra, P.K.; Panigrahi, R.; Aboulnasr, F.; Chava, S.; Kurt, R.; Pawlotsky, J.M.; Wilkens, L.; Osterlund, P.; Hartmann, R.; Balart, L.A.; Wu, T.; Dash, S. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression. Am. J. Pathol., 2016, 186(4), 938-951.
[http://dx.doi.org/10.1016/j.ajpath.2015.11.027] [PMID: 26896692]
[35]
Lu, Y.F.; Mauger, D.M.; Goldstein, D.B.; Urban, T.J.; Weeks, K.M.; Bradrick, S.S. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci. Rep., 2015, 5, 16037.
[http://dx.doi.org/10.1038/srep16037] [PMID: 26531896]
[36]
O’Brien, T.R.; Pfeiffer, R.M.; Paquin, A.; Lang Kuhs, K.A.; Chen, S.; Bonkovsky, H.L.; Edlin, B.R.; Howell, C.D.; Kirk, G.D.; Kuniholm, M.H.; Morgan, T.R.; Strickler, H.D.; Thomas, D.L.; Prokunina-Olsson, L. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J. Hepatol., 2015, 63(5), 1103-1110.
[http://dx.doi.org/10.1016/j.jhep.2015.06.035] [PMID: 26186989]
[37]
Raglow, Z.; Thoma-Perry, C.; Gilroy, R.; Wan, Y.J. IL28B genotype and the expression of ISGs in normal liver. Liver Int., 2013, 33(7), 991-998.
[http://dx.doi.org/10.1111/liv.12148] [PMID: 23522062]
[38]
McFarland, A.P.; Horner, S.M.; Jarret, A.; Joslyn, R.C.; Bindewald, E.; Shapiro, B.A.; Delker, D.A.; Hagedorn, C.H.; Carrington, M.; Gale, M., Jr; Savan, R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol., 2014, 15(1), 72-79.
[http://dx.doi.org/10.1038/ni.2758] [PMID: 24241692]
[39]
Barreau, C.; Paillard, L.; Osborne, H.B. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res., 2006, 33(22), 7138-7150.
[http://dx.doi.org/10.1093/nar/gki1012] [PMID: 16391004]
[40]
UniProtKB - Q8IZI9 (IFNL3_HUMAN). Available at: http://www.uniprot.org/uniprot/Q8IZI9[Accessed March 11, 2018].
[41]
Dumoutier, L.; Tounsi, A.; Michiels, T.; Sommereyns, C.; Kotenko, S.V.; Renauld, J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem., 2004, 279(31), 32269-32274.
[http://dx.doi.org/10.1074/jbc.M404789200] [PMID: 15166220]
[42]
Dumoutier, L.; Lejeune, D.; Hor, S.; Fickenscher, H.; Renauld, J.C. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem. J., 2003, 370(Pt 2), 391-396.
[http://dx.doi.org/10.1042/bj20021935] [PMID: 12521379]
[43]
Popov, A.; Abdullah, Z.; Wickenhauser, C.; Saric, T.; Driesen, J.; Hanisch, F.G.; Domann, E.; Raven, E.L.; Dehus, O.; Hermann, C.; Eggle, D.; Debey, S.; Chakraborty, T.; Krönke, M.; Utermöhlen, O.; Schultze, J.L. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest., 2006, 116(12), 3160-3170.
[http://dx.doi.org/10.1172/JCI28996] [PMID: 17111046]
[44]
Bianchi, M.; Bertini, R.; Ghezzi, P. Induction of indoleamine dioxygenase by interferon in mice: a study with different recombinant interferons and various cytokines. Biochem. Biophys. Res. Commun., 1988, 152(1), 237-242.
[http://dx.doi.org/10.1016/S0006-291X(88)80705-8] [PMID: 3128977]
[45]
Fox, J.M.; Crabtree, J.M.; Sage, L.K.; Tompkins, S.M.; Tripp, R.A. Interferon lambda upregulates IDO1 expression in respiratory epithelial cells after influenza virus infection. J. Interferon Cytokine Res., 2015, 35(7), 554-562.
[http://dx.doi.org/10.1089/jir.2014.0052] [PMID: 25756191]
[46]
Xu, H.; Oriss, T.B.; Fei, M.; Henry, A.C.; Melgert, B.N.; Chen, L.; Mellor, A.L.; Munn, D.H.; Irvin, C.G.; Ray, P.; Ray, A. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. USA, 2008, 105(18), 6690-6695.
[http://dx.doi.org/10.1073/pnas.0708809105] [PMID: 18436652]
[47]
Xu, H.; Zhang, G.X.; Ciric, B.; Rostami, A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol. Lett., 2008, 121(1), 1-6.
[http://dx.doi.org/10.1016/j.imlet.2008.08.008] [PMID: 18824197]
[48]
Murakawa, M.; Asahina, Y.; Nakagawa, M.; Sakamoto, N.; Nitta, S.; Kusano-Kitazume, A.; Watanabe, T.; Kawai-Kitahata, F.; Otani, S.; Taniguchi, M.; Goto, F.; Nishimura-Sakurai, Y.; Itsui, Y.; Azuma, S.; Kakinuma, S.; Watanabe, M. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J. Gastroenterol. Hepatol., 2015, 30(6), 1075-1084.
[http://dx.doi.org/10.1111/jgh.12902] [PMID: 25611696]
[49]
Morrow, M.P.; Yan, J.; Pankhong, P.; Ferraro, B.; Lewis, M.G.; Khan, A.S.; Sardesai, N.Y.; Weiner, D.B. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vaccine Immunol., 2010, 17(10), 1493-1499.
[http://dx.doi.org/10.1128/CVI.00181-10] [PMID: 20685940]
[50]
Morrow, M.P.; Pankhong, P.; Laddy, D.J.; Schoenly, K.A.; Yan, J.; Cisper, N.; Weiner, D.B. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood, 2009, 113(23), 5868-5877.
[http://dx.doi.org/10.1182/blood-2008-11-190520] [PMID: 19304955]
[51]
de Groen, R.A.; Mcphee, F.; Friborg, J.; Janssen, H.L.; Boonstra, A. Endogenous IFNλ in viral hepatitis patients. J. Interferon Cytokine Res., 2014, 34(7), 552-556.
[http://dx.doi.org/10.1089/jir.2013.0068] [PMID: 24433037]
[52]
Diegelmann, J.; Beigel, F.; Zitzmann, K.; Kaul, A.; Göke, B.; Auernhammer, C.J.; Bartenschlager, R.; Diepolder, H.M.; Brand, S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One, 2010, 5(12)e15200
[http://dx.doi.org/10.1371/journal.pone.0015200] [PMID: 21170333]
[53]
Dellgren, C.; Gad, H.H.; Hamming, O.J.; Melchjorsen, J.; Hartmann, R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun., 2009, 10(2), 125-131.
[http://dx.doi.org/10.1038/gene.2008.87] [PMID: 18987645]
[54]
Shi, X.; Pan, Y.; Wang, M.; Wang, D. Li. W.; Jiang, T.; Zhang, P.; Chi, X.; Jiang, Y.; Gao, Y.; Zhong, J.; Sun, B.; Xu, D.; Jiang, J.; Niu, J. IL28B genetic variation is associat-ed with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One, 2012, 7e37054
[http://dx.doi.org/10.1371/journal.pone.0037054] [PMID: 22649509]
[55]
Grzegorzewska, A.E.; Świderska, M.K.; Mostowska, A.; Warchoł, W.; Jagodziński, P.P. Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients. Vaccine, 2016, 34(41), 4866-4874.
[http://dx.doi.org/10.1016/j.vaccine.2016.08.073] [PMID: 27595449]
[56]
Li, W.; Jiang, Y.; Jin, Q.; Shi, X.; Jin, J.; Gao, Y.; Pan, Y.; Zhang, H.; Jiang, J.; Niu, J. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int., 2011, 31(8), 1118-1126.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02507.x] [PMID: 21745278]
[57]
Aoki, Y.; Sugiyama, M.; Murata, K.; Yoshio, S.; Kurosaki, M.; Hashimoto, S.; Yatsuhashi, H.; Nomura, H.; Kang, J.H.; Takeda, T.; Naito, S.; Kimura, T.; Yamagiwa, Y.; Korenaga, M.; Imamura, M.; Masaki, N.; Izumi, N.; Kage, M.; Mizokami, M.; Kanto, T. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J. Gastroenterol., 2015, 50(8), 894-902.
[http://dx.doi.org/10.1007/s00535-014-1023-2] [PMID: 25501286]
[58]
Ank, N.; West, H.; Bartholdy, C.; Eriksson, K.; Thomsen, A.R.; Paludan, S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol., 2006, 80(9), 4501-4509.
[http://dx.doi.org/10.1128/JVI.80.9.4501-4509.2006] [PMID: 16611910]
[59]
Sirén, J.; Pirhonen, J.; Julkunen, I.; Matikainen, S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J. Immunol., 2005, 174(4), 1932-1937.
[http://dx.doi.org/10.4049/jimmunol.174.4.1932] [PMID: 15699120]
[60]
Spann, K.M.; Tran, K.C.; Chi, B.; Rabin, R.L.; Collins, P.L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J. Virol. , 2004, 78(8), 4363-4369.
[http://dx.doi.org/10.1128/JVI.78.8.4363-4369.2004] [PMID: 15047850]
[61]
Brand, S.; Beigel, F.; Olszak, T.; Zitzmann, K.; Eichhorst, S.T.; Otte, J.M.; Diebold, J.; Diepolder, H.; Adler, B.; Auernhammer, C.J.; Göke, B.; Dambacher, J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289(5), G960-G968.
[http://dx.doi.org/10.1152/ajpgi.00126.2005] [PMID: 16051921]
[62]
Coccia, E.M.; Severa, M.; Giacomini, E.; Monneron, D.; Remoli, M.E.; Julkunen, I.; Cella, M.; Lande, R.; Uzé, G. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol., 2004, 34(3), 796-805.
[http://dx.doi.org/10.1002/eji.200324610] [PMID: 14991609]
[63]
Osterlund, P.; Veckman, V.; Sirén, J.; Klucher, K.M.; Hiscott, J.; Matikainen, S.; Julkunen, I. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J. Virol., 2005, 79(15), 9608-9617.
[http://dx.doi.org/10.1128/JVI.79.15.9608-9617.2005] [PMID: 16014923]
[64]
Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; Ito, Y.; Mita, E.; Tanaka, E.; Mochida, S.; Murawaki, Y.; Honda, M.; Sakai, A.; Hiasa, Y.; Nishiguchi, S.; Koike, A.; Sakaida, I.; Imamura, M.; Ito, K.; Yano, K.; Masaki, N.; Sugauchi, F.; Izumi, N.; Tokunaga, K.; Mizokami, M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet., 2009, 41(10), 1105-1109.
[http://dx.doi.org/10.1038/ng.449] [PMID: 19749757]
[65]
Fukuhara, T.; Taketomi, A.; Motomura, T.; Okano, S.; Ninomiya, A.; Abe, T.; Uchiyama, H.; Soejima, Y.; Shirabe, K.; Matsuura, Y.; Maehara, Y. Variants in IL28B in liver recipients and donors correlate with response to peginterferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology, 2010, 139, 1577-1585.
[66]
Tissari, J.; Sirén, J.; Meri, S.; Julkunen, I.; Matikainen, S. IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J. Immunol., 2005, 174(7), 4289-4294.
[http://dx.doi.org/10.4049/jimmunol.174.7.4289] [PMID: 15778392]
[67]
Wieland, S.; Makowska, Z.; Campana, B.; Calabrese, D.; Dill, M.T.; Chung, J.; Chisari, F.V.; Heim, M.H. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology, 2014, 59(6), 2121-2130.
[http://dx.doi.org/10.1002/hep.26770] [PMID: 24122862]
[68]
Abe, H.; Hayes, C.N.; Ochi, H.; Maekawa, T.; Tsuge, M.; Miki, D.; Mitsui, F.; Hiraga, N.; Imamura, M.; Takahashi, S.; Kubo, M.; Nakamura, Y.; Chayama, K. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol., 2011, 54(6), 1094-1101.
[http://dx.doi.org/10.1016/j.jhep.2010.09.019] [PMID: 21145800]
[69]
Larrea, E.; Riezu-Boj, J.I.; Gil-Guerrero, L.; Casares, N.; Aldabe, R.; Sarobe, P.; Civeira, M.P.; Heeney, J.L.; Rollier, C.; Verstrepen, B.; Wakita, T.; Borrás-Cuesta, F.; Lasarte, J.J.; Prieto, J. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol., 2007, 81(7), 3662-3666.
[http://dx.doi.org/10.1128/JVI.02248-06] [PMID: 17229698]
[70]
Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 2010, 466(7308), 835-840.
[http://dx.doi.org/10.1038/nature09267] [PMID: 20703300]
[71]
O’Neill, L.A.; Sheedy, F.J.; McCoy, C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol., 2011, 11(3), 163-175.
[http://dx.doi.org/10.1038/nri2957] [PMID: 21331081]
[72]
Al-Qahtani, A.; Al-Anazi, M.; Abdo, A.A.; Sanai, F.M.; Al-Hamoudi, W.; Alswat, K.A.; Al-Ashgar, H.I.; Khan, M.Q.; Albenmousa, A.; Khalaf, N.; Viswan, N.; Al-Ahdal, M.N. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J. Immunol. Res., 2015, •••2015768470
[http://dx.doi.org/10.1155/2015/768470] [PMID: 25811035]
[73]
Neumann, A.U.; Lam, N.P.; Dahari, H.; Gretch, D.R.; Wiley, T.E.; Layden, T.J.; Perelson, A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 1998, 282(5386), 103-107.
[http://dx.doi.org/10.1126/science.282.5386.103] [PMID: 9756471]
[74]
Villano, S.A.; Vlahov, D.; Nelson, K.E.; Cohn, S.; Thomas, D.L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 1999, 29(3), 908-914.
[http://dx.doi.org/10.1002/hep.510290311] [PMID: 10051497]
[75]
Thomas, D.L.; Thio, C.L.; Martin, M.P.; Qi, Y.; Ge, D.; O’Huigin, C.; Kidd, J.; Kidd, K.; Khakoo, S.I.; Alexander, G.; Goedert, J.J.; Kirk, G.D.; Donfield, S.M.; Rosen, H.R.; Tobler, L.H.; Busch, M.P.; McHutchison, J.G.; Goldstein, D.B.; Carrington, M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461(7265), 798-801.
[http://dx.doi.org/10.1038/nature08463] [PMID: 19759533]
[76]
Fabris, C.; Falleti, E.; Cussigh, A.; Bitetto, D.; Fontanini, E.; Bignulin, S.; Cmet, S.; Fornasiere, E.; Fumolo, E.; Fangazio, S.; Cerutti, A.; Minisini, R.; Pirisi, M.; Toniutto, P. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol., 2011, 54(4), 716-722.
[http://dx.doi.org/10.1016/j.jhep.2010.07.019] [PMID: 21146242]
[77]
Eurich, D.; Boas-Knoop, S.; Bahra, M.; Neuhaus, R.; Somasundaram, R.; Neuhaus, P.; Neumann, U.; Seehofer, D. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation, 2012, 93(6), 644-649.
[http://dx.doi.org/10.1097/TP.0b013e318244f774] [PMID: 22411462]
[78]
Bochud, P.Y.; Bibert, S.; Kutalik, Z.; Patin, E.; Guergnon, J.; Nalpas, B.; Goossens, N.; Kuske, L.; Müllhaupt, B.; Gerlach, T.; Heim, M.H.; Moradpour, D.; Cerny, A.; Malinverni, R.; Regenass, S.; Dollenmaier, G.; Hirsch, H.; Martinetti, G.; Gorgiewski, M.; Bourlière, M.; Poynard, T.; Theodorou, I.; Abel, L.; Pol, S.; Dufour, J.F.; Negro, F. Swiss Hepatitis C Cohort Study Group. ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55(2), 384-394.
[http://dx.doi.org/10.1002/hep.24678] [PMID: 22180014]
[79]
Rauch, A.; Kutalik, Z.; Descombes, P.; Cai, T.; Di Iulio, J.; Mueller, T.; Bochud, M.; Battegay, M.; Bernasconi, E.; Bo-rovicka, J.; Colombo, S.; Cerny, A.; Dufour, J.F.; Furrer, H.; Günthard, H.F.; Heim, M.; Hirschel, B.; Malinverni, R.; Mo-radpour, D.; Müllhaupt, B.; Witteck, A.; Beckmann, J.S.; Berg, T.; Bergmann, S.; Negro, F.; Telenti, A.; Bochud, P.Y. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 2010, 54(6), 1094-1101.
[http://dx.doi.org/10.1053/j.gastro.2009.12.056] [PMID: 20060832]
[80]
Grzegorzewska, A.E.; Jodłowska, E.; Mostowska, A.; Jagodziński, P. Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients. Pol. Arch. Med. Wewn., 2015, 125(12), 894-902.
[http://dx.doi.org/10.20452/pamw.3205] [PMID: 26658164]
[81]
Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; Sulkowski, M.; McHutchison, J.G.; Goldstein, D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461(7262), 399-401.
[http://dx.doi.org/10.1038/nature08309] [PMID: 19684573]
[82]
Suppiah, V.; Moldovan, M.; Ahlenstiel, G.; Berg, T.; Weltman, M.; Abate, M.L.; Bassendine, M.; Spengler, U.; Dore, G.J.; Powell, E.; Riordan, S.; Sheridan, D.; Smedile, A.; Fragomeli, V.; Müller, T.; Bahlo, M.; Stewart, G.J.; Booth, D.R.; George, J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet., 2009, 41(10), 1100-1104.
[http://dx.doi.org/10.1038/ng.447] [PMID: 19749758]
[83]
Chu, T.W.; Kulkarni, R.; Gane, E.J.; Roberts, S.K.; Stedman, C.; Angus, P.W.; Ritchie, B.; Lu, X.Y.; Ipe, D.; Lopatin, U.; Germer, S.; Iglesias, V.A.; Elston, R.; Smith, P.F.; Shulman, N.S. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology, 2012, 142(4), 790-795.
[http://dx.doi.org/10.1053/j.gastro.2011.12.057] [PMID: 22248659]
[84]
Ito, K.; Higami, K.; Masaki, N.; Sugiyama, M.; Mukaide, M.; Saito, H.; Aoki, Y.; Sato, Y.; Imamura, M.; Murata, K.; Nomura, H.; Hige, S.; Adachi, H.; Hino, K.; Yatsuhashi, H.; Orito, E.; Kani, S.; Tanaka, Y.; Mizokami, M. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol., 2011, 49(5), 1853-1860.
[http://dx.doi.org/10.1128/JCM.02139-10] [PMID: 21389156]
[85]
Bibert, S.; Roger, T.; Calandra, T.; Bochud, M.; Cerny, A.; Semmo, N.; Duong, F.H.; Gerlach, T.; Malinverni, R.; Moradpour, D.; Negro, F.; Müllhaupt, B.; Bochud, P.Y. Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med., 2013, 210(6), 1109-1116.
[http://dx.doi.org/10.1084/jem.20130012] [PMID: 23712427]
[86]
Franco, S.; Aparicio, E.; Parera, M.; Clotet, B.; Tural, C.; Martinez, M.A. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS, 2014, 28(1), 133-136.
[http://dx.doi.org/10.1097/QAD.0000000000000052] [PMID: 24072198]
[87]
Meissner, E.G.; Bon, D.; Prokunina-Olsson, L.; Tang, W.; Masur, H.; O’Brien, T.R.; Herrmann, E.; Kottilil, S.; Osinusi, A. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J. Infect. Dis., 2014, 209(11), 1700-1704.
[http://dx.doi.org/10.1093/infdis/jit827] [PMID: 24367041]
[88]
Urban, T.J.; Thompson, A.J.; Bradrick, S.S.; Fellay, J.; Schuppan, D.; Cronin, K.D.; Hong, L.; McKenzie, A.; Patel, K.; Shianna, K.V.; McHutchison, J.G.; Goldstein, D.B.; Afdhal, N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology, 2010, 52(6), 1888-1896.
[http://dx.doi.org/10.1002/hep.23912] [PMID: 20931559]
[89]
Honda, M.; Shirasaki, T.; Shimakami, T.; Sakai, A.; Horii, R.; Arai, K.; Yamashita, T.; Sakai, Y.; Yamashita, T.; Okada, H.; Murai, K.; Nakamura, M.; Mizukoshi, E.; Kaneko, S. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology, 2014, 59(3), 828-838.
[http://dx.doi.org/10.1002/hep.26788] [PMID: 24311440]
[90]
Dill, M.T.; Duong, F.H.; Vogt, J.E.; Bibert, S.; Bochud, P.Y.; Terracciano, L.; Papassotiropoulos, A.; Roth, V.; Heim, M.H. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology, 2011, 140(3), 1021-1031.
[http://dx.doi.org/10.1053/j.gastro.2010.11.039] [PMID: 21111740]
[91]
Asselah, T.; Bieche, I.; Narguet, S.; Sabbagh, A.; Laurendeau, I.; Ripault, M.P.; Boyer, N.; Martinot-Peignoux, M.; Valla, D.; Vidaud, M.; Marcellin, P. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut, 2008, 57(4), 516-524.
[http://dx.doi.org/10.1136/gut.2007.128611] [PMID: 17895355]
[92]
Chen, L.; Borozan, I.; Feld, J.; Sun, J.; Tannis, L.L.; Coltescu, C.; Heathcote, J.; Edwards, A.M.; McGilvray, I.D. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology, 2005, 128(5), 1437-1444.
[http://dx.doi.org/10.1053/j.gastro.2005.01.059] [PMID: 15887125]
[93]
Honda, M.; Sakai, A.; Yamashita, T.; Nakamoto, Y.; Mizukoshi, E.; Sakai, Y.; Yamashita, T.; Nakamura, M.; Shirasaki, T.; Horimoto, K.; Tanaka, Y.; Tokunaga, K.; Mizokami, M.; Kaneko, S. Hokuriku Liver Study Group.Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology, 2010, 139(2), 499-509.
[http://dx.doi.org/10.1053/j.gastro.2010.04.049] [PMID: 20434452]
[94]
Friborg, J.; Levine, S.; Chen, C.; Sheaffer, A.K.; Chaniewski, S.; Voss, S.; Lemm, J.A.; McPhee, F. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob. Agents Chemother., 2013, 57(3), 1312-1322.
[http://dx.doi.org/10.1128/AAC.02239-12] [PMID: 23274666]
[95]
Duong, F.H.; Trincucci, G.; Boldanova, T.; Calabrese, D.; Campana, B.; Krol, I.; Durand, S.C.; Heydmann, L.; Zeisel, M.B.; Baumert, T.F.; Heim, M.H. IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J. Exp. Med., 2014, 211(5), 857-868.
[http://dx.doi.org/10.1084/jem.20131557] [PMID: 24752298]
[96]
Chinnaswamy, S.; Chatterjee, S.; Boopathi, R.; Mukherjee, S.; Bhattacharjee, S.; Kundu, T.K. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription. PLoS One, 2013, 8(10)e75495
[http://dx.doi.org/10.1371/journal.pone.0075495] [PMID: 24116050]
[97]
de Castellarnau, M.; Aparicio, E.; Parera, M.; Franco, S.; Tural, C.; Clotet, B.; Martínez, M.A. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One, 2012, 7(2)e31016
[http://dx.doi.org/10.1371/journal.pone.0031016] [PMID: 22328925]
[98]
Golden-Mason, L.; Bambha, K.M.; Cheng, L.; Howell, C.D.; Taylor, M.W.; Clark, P.J.; Afdhal, N.; Rosen, H.R. Virahep-C Study Group.Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology, 2011, 54(5), 1559-1569.
[http://dx.doi.org/10.1002/hep.24556] [PMID: 21983945]
[99]
Dumaidi, K.; Al-Jawabreh, A. Persistence of anti-HBs among Palestinian medical students after 18 - 22 years of vaccination: a cross-sectional study. Hepat. Mon., 2015, 15(11)e29325
[http://dx.doi.org/10.5812/hepatmon.29325] [PMID: 26834785]
[100]
Arias-Moliz, M.T.; Rojas, L.; Liébana-Cabanillas, F.; Bernal, C.; Castillo, F.; Rodríguez-Archilla, A.; Castillo, A.; Liébana, J. Serologic control against hepatitis B virus among dental students of the University of Granada, Spain. Med. Oral Patol. Oral Cir. Bucal, 2015, 20(5), e566-e571.
[http://dx.doi.org/10.4317/medoral.20579] [PMID: 26241457]
[101]
Al Ghamdi, S.S.; Fallatah, H.I.; Fetyani, D.M.; Al-Mughales, J.A.; Gelaidan, A.T. Long-term efficacy of the hepatitis B vaccine in a high-risk group. J. Med. Virol., 2013, 85(9), 1518-1522.
[http://dx.doi.org/10.1002/jmv.23658] [PMID: 23852676]
[102]
Momeni, N.; Ahmad Akhoundi, M.S.; Alavian, S.M.; Shamshiri, A.R.; Norouzi, M.; Mahboobi, N.; Moosavi, N.; Jazayeri, S.M. HBV vaccination status and response to hepatitis B vaccine among Iranian dentists, correlation with risk factors and preventive measures. Hepat. Mon., 2014, 15(1)e20014
[http://dx.doi.org/10.5812/hepatmon.20014] [PMID: 25741367]
[103]
Morrow, M.P.; Yan, J.; Pankhong, P.; Shedlock, D.J.; Lewis, M.G.; Talbott, K.; Toporovski, R.; Khan, A.S.; Sardesai, N.Y.; Weiner, D.B. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol. Ther., 2010, 18(9), 1714-1723.
[http://dx.doi.org/10.1038/mt.2010.118] [PMID: 20571540]
[104]
Lonnemann, G.; Novick, D.; Rubinstein, M.; Dinarello, C.A. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin. Nephrol., 2003, 60(5), 327-334.
[http://dx.doi.org/10.5414/CNP60327] [PMID: 14640238]
[105]
Pawlak, K.; Myśliwiec, M.; Pawlak, D. Effect of diabetes and oxidative stress on plasma CCL23 levels in patients with severe chronic kidney disease. Pol. Arch. Med. Wewn., 2014, 124(9), 459-466.
[http://dx.doi.org/10.20452/pamw.2405] [PMID: 24995525]
[106]
Grzegorzewska, A.E.; Wobszal, P.; Jagodziński, P.P. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press. Res., 2012, 35(1), 1-8.
[http://dx.doi.org/10.1159/000329932] [PMID: 21832842]
[107]
Jodłowska-Siewert, E.; Jagodziński, P.P.; Grzegorzewska, A.E. The titers of antibodies to the surface antigen of hepatitis B virus after vaccination in relation to polymorphisms in the immunity-related genes – a prospective study among hemodialysis patients. Pol. Arch. Int. Med., 2017, 127, 481-489.
[PMID: 28817541]
[108]
Grzegorzewska, A.E.; Wobszal, P.M.; Sowińska, A.; Mostowska, A.; Jagodziński, P.P. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol. Biol. Rep., 2013, 40(12), 6899-6911.
[http://dx.doi.org/10.1007/s11033-013-2809-7] [PMID: 24158609]
[109]
Grzegorzewska, A.E.; Pajzderski, D.; Sowińska, A.; Jagodziński, P.P. Polymporphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. Pol. Arch. Med. Wewn., 2014, 124(1-2), 10-18.
[PMID: 24382482]
[110]
Gu, L.; Tseng, S.; Horner, R.M.; Tam, C.; Loda, M.; Rollins, B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature, 2000, 404(6776), 407-411.
[http://dx.doi.org/10.1038/35006097] [PMID: 10746730]
[111]
Eleftheriadis, T.; Sparopoulou, T.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I.; Galaktidou, G. Suppression of humoral immune response to hepatitis B surface antigen vaccine in BALB/c mice by 1-methyl-tryptophan co-administration. Daru, 2011, 19(3), 236-239.
[PMID: 22615663]
[112]
Mao, R.; Zhang, J.; Jiang, D.; Cai, D.; Levy, J.M.; Cuconati, A.; Block, T.M.; Guo, J.T.; Guo, H. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J. Virol., 2011, 85(2), 1048-1057.
[http://dx.doi.org/10.1128/JVI.01998-10] [PMID: 21084489]
[113]
Schmidt, S.V.; Schultze, J.L. New insights into IDO biology in bacterial and viral infections. Front. Immunol., 2014, 5, 384.
[http://dx.doi.org/10.3389/fimmu.2014.00384] [PMID: 25157255]
[114]
Lampertico, P.; Viganò, M.; Cheroni, C.; Facchetti, F.; Invernizzi, F.; Valveri, V.; Soffredini, R.; Abrignani, S.; De Francesco, R.; Colombo, M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology, 2013, 57(3), 890-896.
[http://dx.doi.org/10.1002/hep.25749] [PMID: 22473858]
[115]
Tang, S.; Yue, M.; Wang, J.; Zhang, Y.; Yu, R.; Su, J.; Peng, Z.; Wang, J. Associations of IFN-γ rs2430561 T/A, IL28B rs12979860 C/T and ERα rs2077647 T/C polymorphisms with outcomes of hepatitis B virus infection: a meta-analysis. J. Biomed. Res., 2014, 28(6), 484-493.
[PMID: 25469118]
[116]
Trépo, C.; Chan, H.L.; Lok, A. Hepatitis B virus infection. Lancet, 2014, 384(9959), 2053-2063.
[http://dx.doi.org/10.1016/S0140-6736(14)60220-8] [PMID: 24954675]
[117]
Rukov, J.L.; Gravesen, E.; Mace, M.L.; Hofman-Bang, J.; Vinther, J.; Andersen, C.B.; Lewin, E.; Olgaard, K. Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. Am. J. Physiol. Renal Physiol., 2016, 310(6), F477-F491.
[http://dx.doi.org/10.1152/ajprenal.00472.2015] [PMID: 26739890]
[118]
Vaziri, N.D.; Pahl, M.V.; Crum, A.; Norris, K. Effect of uremia on structure and function of immune system. J. Ren. Nutr., 2012, 22(1), 149-156.
[http://dx.doi.org/10.1053/j.jrn.2011.10.020] [PMID: 22200433]
[119]
Pertosa, G.; Grandaliano, G.; Gesualdo, L.; Schena, F.P. Clinical relevance of cytokine production in hemodialysis. Kidney Int. Suppl., 2000, 76, S104-S111.
[http://dx.doi.org/10.1046/j.1523-1755.2000.07613.x] [PMID: 10936806]
[120]
Teta, D. Adipokines as uremic toxins. J. Ren. Nutr., 2012, 22(1), 81-85.
[http://dx.doi.org/10.1053/j.jrn.2011.10.029] [PMID: 22200420]
[121]
Mabuchi, H.; Nakahashi, H. Analysis of small peptide in uremic serum by high-performance liquid chromatography. J. Chromatogr. A, 1982, 228, 292-297.
[http://dx.doi.org/10.1016/S0378-4347(00)80443-0] [PMID: 7076752]
[122]
Laveborn, E.; Lindmark, K.; Skagerlind, M.; Stegmayr, B. NT-proBNP and troponin T levels differ after haemodialysis with a low versus high flux membrane. Int. J. Artif. Organs, 2015, 38(2), 69-75.
[http://dx.doi.org/10.5301/ijao.5000387] [PMID: 25744196]
[123]
Susantitaphong, P.; Siribamrungwong, M.; Jaber, B.L. Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant., 2013, 28(11), 2859-2874.
[http://dx.doi.org/10.1093/ndt/gft396] [PMID: 24081858]
[124]
Witte, K.; Witte, E.; Sabat, R.; Wolk, K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev., 2010, 21(4), 237-251.
[http://dx.doi.org/10.1016/j.cytogfr.2010.04.002] [PMID: 20655797]
[125]
Yu, M.L.; Dai, C.Y.; Huang, C.F.; Lee, J.J.; Yeh, M.L.; Yeh, S.M.; Kuo, H.T.; Huang, J.F.; Chang, J.M.; Chen, H.C.; Juo, S.H.; Hwang, S.J.; Chuang, W.L. FORMOSA-LIKE group.High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J. Hepatol., 2014, 60(2), 253-259.
[http://dx.doi.org/10.1016/j.jhep.2013.09.023] [PMID: 24096049]
[126]
Duggal, P.; Thio, C.L.; Wojcik, G.L.; Goedert, J.J.; Mangia, A.; Latanich, R.; Kim, A.Y.; Lauer, G.M.; Chung, R.T.; Peters, M.G.; Kirk, G.D.; Mehta, S.H.; Cox, A.L.; Khakoo, S.I.; Alric, L.; Cramp, M.E.; Donfield, S.M.; Edlin, B.R.; Tobler, L.H.; Busch, M.P.; Alexander, G.; Rosen, H.R.; Gao, X.; Abdel-Hamid, M.; Apps, R.; Carrington, M.; Thomas, D.L. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann. Intern. Med., 2013, 158(4), 235-245.
[http://dx.doi.org/10.7326/0003-4819-158-4-201302190-00003] [PMID: 23420232]
[127]
Meng, Z.F.; Wang, H.J.; Yao, X.; Wang, X.Y.; Wen, Y.M.; Dai, J.X.; Xie, Y.H.; Xu, J.Q. Immunization with HBsAg-Fc fusion protein induces a predominant production of Th1 cytokines and reduces HBsAg level in transgenic mice. Chin. Med. J. (Engl.), 2012, 125(18), 3266-3272.
[PMID: 22964321]
[128]
Grzegorzewska, A.E.; Świderska, M.K.; Mostowska, A.; Jagodziński, P.P. Circulating interferon-λ3, responsiveness to HBV vaccination, and HBV/HCV infections in haemodialysis patients. BioMed Res. Int., 2017, •••20173713025
[http://dx.doi.org/10.1155/2017/3713025] [PMID: 29226133]
[129]
Liang, T.J.; Ghany, M.G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med., 2013, 368(20), 1907-1917.
[http://dx.doi.org/10.1056/NEJMra1213651] [PMID: 23675659]
[130]
Cartwright, E.J.; Miller, L. Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepat. Med., 2013, 5, 53-61.
[PMID: 24696624]
[131]
Boglione, L.; Cardellino, C.S.; Cusato, J.; De Nicolò, A.; Cariti, G.; Di Perri, G.; D’Avolio, A. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: a pharmacogenetic prospective study. Infect. Genet. Evol., 2017, 51, 167-172.
[http://dx.doi.org/10.1016/j.meegid.2017.03.014] [PMID: 28315743]
[132]
Ferreira, C. S.; Abreu, R.M.; da Silva, M.C.; Ferreira, A.S.; Nasser, P.D.; Carrilho, F.J.; Ono, S.K. A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS One, 2013, 8(10)e78142
[http://dx.doi.org/10.1371/journal.pone.0078142] [PMID: 24167602]
[133]
Meissner, E.G.; Wu, D.; Osinusi, A.; Bon, D.; Virtaneva, K.; Sturdevant, D.; Porcella, S.; Wang, H.; Herrmann, E.; McHutchison, J.; Suffredini, A.F.; Polis, M.; Hewitt, S.; Prokunina-Olsson, L.; Masur, H.; Fauci, A.S.; Kottilil, S. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J. Clin. Invest., 2014, 124(8), 3352-3363.
[http://dx.doi.org/10.1172/JCI75938] [PMID: 24983321]
[134]
Andersen, H.; Meyer, J.; Freeman, J.; Doyle, S.E.; Klucher, K.; Miller, D.M.; Hausman, D.; Hillson, J.L. Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic. J. Clin. Transl. Hepatol., 2013, 1(2), 116-124.
[PMID: 26357610]
[135]
Muir, A.J.; Arora, S.; Everson, G.; Flisiak, R.; George, J.; Ghalib, R.; Gordon, S.C.; Gray, T.; Greenbloom, S.; Hassanein, T.; Hillson, J.; Horga, M.A.; Jacobson, I.M.; Jeffers, L.; Kowdley, K.V.; Lawitz, E.; Lueth, S.; Rodriguez-Torres, M.; Rustgi, V.; Shemanski, L.; Shiffman, M.L.; Srinivasan, S.; Vargas, H.E.; Vierling, J.M.; Xu, D.; Lopez-Talavera, J.C.; Zeuzem, S. EMERGE study group.A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol., 2014, 61(6), 1238-1246.
[http://dx.doi.org/10.1016/j.jhep.2014.07.022] [PMID: 25064437]
[136]
Nelson, M.; Rubio, R.; Lazzarin, A.; Romanova, S.; Luetkemeyer, A.; Conway, B.; Molina, J.M.; Xu, D.; Srinivasan, S.; Portsmouth, S. Safety and efficacy of pegylated interferon lambda, ribavirin, and daclatasvir in HCV and HIV-coinfected patients. J. Interferon Cytokine Res., 2017, 37(3), 103-111.
[http://dx.doi.org/10.1089/jir.2016.0082] [PMID: 28282271]
[137]
Chan, H.L.Y.; Ahn, S.H.; Chang, T.T.; Peng, C.Y.; Wong, D.; Coffin, C.S.; Lim, S.G.; Chen, P.J.; Janssen, H.L.A.; Marcellin, P.; Serfaty, L.; Zeuzem, S.; Cohen, D.; Critelli, L.; Xu, D.; Wind-Rotolo, M.; Cooney, E. LIRA-B Study Team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J. Hepatol., 2016, 64(5), 1011-1019.
[http://dx.doi.org/10.1016/j.jhep.2015.12.018] [PMID: 26739688]
[138]
Attia, D.; El Saeed, K.; Elakel, W.; El Baz, T.; Omar, A.; Yosry, A.; Elsayed, M.H.; Said, M.; El Raziky, M.; Anees, M.; Doss, W.; El Shazly, Y.; Wedemeyer, H.; Esmat, G. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment. Pharmacol. Ther., 2018, 47(9), 1296-1305.
[http://dx.doi.org/10.1111/apt.14538] [PMID: 29504152]
[139]
Renzulli, M.; Buonfiglioli, F.; Conti, F.; Brocchi, S.; Serio, I.; Foschi, F.G.; Caraceni, P.; Mazzella, G.; Verucchi, G.; Golfieri, R.; Andreone, P.; Brillanti, S. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur. Radiol., 2018, 28(2), 506-513.
[http://dx.doi.org/10.1007/s00330-017-5033-3] [PMID: 28894901]
[140]
Vijgen, L.; Thys, K.; Vandebosch, A.; Van Remoortere, P.; Verloes, R.; De Meyer, S. Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845. Virol. J., 2017, 14(1), 101.
[http://dx.doi.org/10.1186/s12985-017-0760-2] [PMID: 28569206]
[141]
Şanlıdağ, T.; Sayan, M.; Akçalı, S.; Kasap, E.; Buran, T.; Arıkan, A. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1 [Article in Turkish Mikrobiyol. Bul., 2017, 51(2), 145-155.
[PMID: 28566078]
[142]
Li, Z.; Zhang, Y.; Liu, Y.; Shao, X.; Luo, Q.; Cai, Q.; Zhao, Z. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatmentnaive HCV genotype 1b-infected patients in China. Medicine (Baltimore),, 2017, 96(19), e6830.
[http://dx.doi.org/10.1097/MD.0000000000006830] [PMID: 28489763]

Rights & Permissions Print Cite
Article Metrics
47
4
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy